First clinical trials of a vaccine against the new coronavirus will be launched in Germany by the company BioNTech, based in Mainz, in association with the American laboratory Pfizer, announced on Wednesday the competent federal authority.
>> LIVE - Coronavirus: follow the evolution of the situation on Wednesday April 22
These clinical trials will initially be carried out on 200 healthy volunteers aged 18 to 55, said the Paul Ehrlich Institute on its website, adding that it was "only the fourth human trial" in the world of a Covid-19 vaccine.
CORONAVIRUS ESSENTIALS
> Can France hope for a more favorable scenario than Italy?
> Are women and people with blood type O more resistant?
> Are certain serious forms linked to a genetic factor?
> How will the distribution of masks take place in France?
> Back to school on May 11: under what conditions?
> How to keep sleep during confinement?
More than thirty studies and trials aimed at developing treatments against covid-19 have been launched in France, out of a total of 860 worldwide, detailed on Sunday Professor Florence Ader, infectiologist at the Croix-Rousse hospital in Lyon and responsible for one of these research programs. With a total of 1,600 patients already included in trials in the country, "the active search for a treatment against the coronavirus is extremely active in France", underlined the infectiologist, during a press conference in Matignon.